SHANGHAI, Feb. 23, 2024/PRNewswire/ -- Yahong Pharmaceutical (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors, recently announced that the results of the APL-1702 international multi-center phase III clinical trial of its non-surgical treatment of cervical HSIL product were selected for the American Society of Gynecologic Oncology (SGO) Late Breaking Oral Presentation (SGO) held on March 16-18, 2024, and will release clinical trial data in the form of an oral report.
- Oral report: Long-term efficacy and safety of APL-1702 high-grade squamous intraepithelial lesion (HSIL) of cervical tissue: results from a randomized global phase III study.
SGO is currently one of the most watched events in the field of gynecological oncology in the world. It brings together thousands of top experts and scholars in the field of gynecological oncology from around the world to showcase the latest research progress and best clinical practices in the field of gynecological oncology.
About Yahong Pharmaceutical
Established in March 2010, Yahong Pharmaceutical (stock code: 688176.SH) is a global innovative pharmaceutical company focusing on urogenital tumors and other major diseases. Adhering to the corporate mission of “improving human health and making life more dignified”, Yahong Pharmaceutical aims to become a leading international pharmaceutical company integrating R&D, production and commercialization in the field of treatment, providing the best integrated diagnosis and treatment solutions for patients in China and around the world.
The company insists on innovative technology and products as the core driving force. By building its own R&D platform and core technology, the company thoroughly explores the mechanism of action of drugs and efficiently screens and evaluates drug candidates. Through a complete internal R&D system and global drug development expertise, Yahong Pharmaceutical is committed to launching first-in-class (first-in-class) drugs and other innovative drugs with huge unmet treatment needs in therapeutic areas.
At the same time, through independent research and development and strategic cooperation, Yahong Pharmaceutical has carried out in-depth product pipeline layout around urogenital diseases, paid great attention to cutting-edge technology and treatment trends in this field, discovered and explored unmet clinical needs, carried out forward-looking product planning and life cycle management, and created an advantageous product portfolio covering disease diagnosis to treatment, thus benefiting more patients in China and around the world.